Trial Profile
A Phase I/II, Clinical Trial to Evaluate the Safety and Immune Activation of the Combination of DCVAC/PCa, and ONCOS-102, in Men With Advanced Metastatic Castration-resistant Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs ONCOS 102 (Primary) ; Stapuldencel-T (Primary) ; Cyclophosphamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 26 Mar 2021 According to Eudra, the trial is completed in Czech Republic
- 27 Jan 2021 Status changed from recruiting to discontinued.
- 03 Nov 2020 Planned End Date changed from 1 Apr 2021 to 1 Dec 2021.